[Biological treatment of multiple sclerosis]

P.S. Sorensen; F. Sellebjerg

[Biological treatment of multiple sclerosis]

2 Citations (Scopus)

Abstract

In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate
Udgivelsesdato: 2008/6/9

Original language	Danish
Journal	Ugeskrift for læger
Volume	170
Issue number	24
Pages (from-to)	2156-2159
Number of pages	3
ISSN	0041-5782
Publication status	Published - 2008

Cite this

@article{6159f9509c6511debc73000ea68e967b,

title = "[Biological treatment of multiple sclerosis]",

abstract = "In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate Udgivelsesdato: 2008/6/9",

author = "P.S. Sorensen and F. Sellebjerg",

year = "2008",

language = "Dansk",

volume = "170",

pages = "2156--2159",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - [Biological treatment of multiple sclerosis]

AU - Sorensen, P.S.

AU - Sellebjerg, F.

PY - 2008

Y1 - 2008

N2 - In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate Udgivelsesdato: 2008/6/9

AB - In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate Udgivelsesdato: 2008/6/9

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 2156

EP - 2159

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -